FDA批准Citius制药公司的血液癌治疗,Lymphir, 治疗重新陷入肺癌的T细胞淋巴瘤病人。 FDA approves Citius Pharmaceuticals' blood cancer therapy, Lymphir, for relapsed cutaneous T-cell lymphoma patients.
美国食品和药物管理局批准了Citius Pharmaceuticals的血液癌症治疗Lymphir,用于已经接受过一次系统治疗的复发性皮肤T细胞淋巴瘤患者,这标志着Lymphir和Citius Pharmaceuticals首个FDA批准的产品的首个适用症. The FDA has approved Citius Pharmaceuticals' blood cancer therapy, Lymphir, for relapsed cutaneous T-cell lymphoma patients who have already received one prior systemic therapy, marking the first indication for Lymphir and Citius Pharmaceuticals' first FDA-approved product. Lymphir针对恶性T细胞和Tregs的Interleukin-2受体,为治疗CTCL提供了一种新颖的方法,预计在今后5个月内在美国市场上推出。 Lymphir targets the interleukin-2 receptor on malignant T-cells and Tregs, offering a novel approach to treating CTCL and is expected to launch in the U.S. market within the next five months. 四氯化碳治疗的总体市场估计约为3亿至4亿美元。 The overall market for CTCL treatments is estimated to be around $300-400 million.